Hudson Bay Capital Management LP Invests $2.81 Million in Repligen Corporation $RGEN

Hudson Bay Capital Management LP purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,003 shares of the biotechnology company’s stock, valued at approximately $2,807,000.

A number of other hedge funds have also recently modified their holdings of RGEN. Measured Wealth Private Client Group LLC acquired a new stake in Repligen during the third quarter worth about $29,000. CWM LLC lifted its holdings in Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 135 shares during the last quarter. Johnson Financial Group Inc. purchased a new position in Repligen in the third quarter worth approximately $65,000. Trust Co. of Vermont acquired a new stake in Repligen during the third quarter worth $67,000. Finally, Wilmington Savings Fund Society FSB increased its stake in Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 495 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

RGEN stock opened at $113.88 on Friday. The business has a 50 day moving average price of $140.22 and a 200 day moving average price of $146.69. The stock has a market cap of $6.41 billion, a price-to-earnings ratio of 133.98, a PEG ratio of 2.23 and a beta of 1.14. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $175.77. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The firm’s revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of a number of research analyst reports. UBS Group lowered their price target on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Wells Fargo & Company lowered their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Finally, KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.